Note: This article is written in standard American English and based on verified public reporting, government material, and peer-reviewed analysis. Source links have been omitted for publication use.
Right-to-try has always sold itself like a movie trailer with dramatic music and absolutely no budget for fact-checking. The pitch is irresistible: a dying patient, an experimental drug, a government wall, and one brave law to smash that wall into patriotic confetti. In campaign speeches and press releases, it sounds like compassion with a cape.
In practice, it has often looked more like a vending machine with no snacks inside.
That is why critics keep returning to the same blunt conclusion: right-to-try is not a miracle shortcut. It is a political slogan wrapped around a medical access problem that is much messier than lawmakers like to admit. California learned that lesson early. The rest of the country, apparently, keeps asking for a sequel.
The issue matters because it sits at the intersection of hope, fear, grief, deregulation, and very real scientific uncertainty. Families facing a life-threatening illness do not experience policy as an abstract debate. They experience it at 2 a.m., after another bad scan, while googling words like “experimental,” “trial,” and “please tell me there’s something else.” That desperation deserves honesty, not a glossy brochure dressed up as reform.
What right-to-try was supposed to be
California’s Right to Try Act, added to the state Health and Safety Code after AB 1668 and effective January 1, 2017, allows certain patients with immediately life-threatening conditions to seek investigational drugs, biologics, or devices outside a clinical trial. The federal Right to Try Act, signed in 2018, created a national version of the same idea. Supporters argued that terminally ill patients who had exhausted approved options should not be trapped behind red tape while a potentially useful treatment sat in a lab, a warehouse, or a corporate legal department.
On paper, that sounds humane. And to be fair, the impulse behind it is understandable. Nobody hears “you are out of standard options” and thinks, “Excellent, now let us move carefully through a thicket of procedural nuance.” People want speed. They want access. They want one more door.
But medicine is not a fairy tale, and a Phase 1 trial badge is not a magic wand. Early-stage investigational products are still experimental for a reason. They may be promising. They may be disappointing. They may be dangerous. Often, all three possibilities are standing in the same room, wearing identical coats.
Why critics call it a cruel sham
1. It does not force drug companies to say yes
This is the first big crack in the sales pitch. Right-to-try does not require a manufacturer to provide the investigational product. Not in California. Not under federal law. Not anywhere that actually has to ship the drug.
That means the law creates a “right” that depends on a company’s willingness, supply, risk tolerance, trial strategy, and legal comfort. A patient may qualify on paper and still get nowhere. The company can decline. The company can stay silent. The company can say it does not have enough product, cannot manage the request, or does not want to jeopardize a study already underway. In other words, right-to-try often gives patients permission to ask, not a reliable path to receive.
That is not nothing. But it is also not the triumphant breakthrough its branding implies.
2. Phase 1 does not mean “probably works”
Another problem is how right-to-try turns a very preliminary research milestone into a public symbol of hidden promise. Phase 1 trials are mainly about safety and dosage. They are not designed to prove that a treatment works. They are the scientific equivalent of checking whether the airplane’s wings are attached before promising anyone a pleasant vacation.
That distinction matters. A treatment that has cleared Phase 1 may still fail later because it is ineffective, too toxic, too hard to manufacture, or simply not good enough to justify approval. Right-to-try rhetoric has often treated “passed Phase 1” as if it were shorthand for “one bureaucrat away from a cure.” It is not. That is hope talking in all caps.
3. The FDA already had a pathway
Here is the awkward part for right-to-try evangelists: the United States already had a mechanism for patients seeking access to investigational products outside clinical trials. It is called expanded access, sometimes referred to as compassionate use. The FDA has supported some version of this pathway for decades, and by the agency’s own current account, about 99% of expanded-access requests are allowed to proceed.
That number is not tiny. It is not middling. It is not “the FDA said no because it hates joy.” It is extremely high.
The harder bottleneck has usually been elsewhere: finding a willing manufacturer, handling logistics, securing physician support, navigating institutional review board oversight, managing costs, and figuring out whether the patient is medically stable enough to pursue the option at all. Right-to-try did not magically erase those obstacles. It mainly removed some oversight while leaving the toughest real-world barriers intact.
4. Fewer safeguards can mean more risk
Supporters often frame right-to-try as a compassionate bypass lane. Critics see something else: a pathway with thinner guardrails. Expanded access includes FDA involvement and institutional review board oversight. Right-to-try generally does not. That may sound efficient until you remember why guardrails exist. They are not there because regulators enjoy paperwork the way normal people enjoy brunch. They are there because desperate patients are uniquely vulnerable to wishful thinking, pressure, and selective storytelling.
Even informed consent can become fuzzier in this setting. California’s law contains consent language and some reporting provisions, but right-to-try generally weakens or sidesteps the more structured review culture that accompanies expanded access. That matters when the treatment in question may have uncertain dosing, unproven benefit, poorly understood adverse effects, and a price tag capable of causing a second medical emergency in the family checking account.
And yes, money is part of this conversation. Critics have long noted that right-to-try can drift into “right to buy.” The legal right to request an investigational treatment is not the same thing as the practical ability to afford it, travel for it, monitor it, or recover from complications it may trigger.
The real-world track record is a buzzkill for the marketing department
If right-to-try were the lifeline its loudest advocates promised, by now we would expect a parade of clear success stories, robust utilization data, and measurable evidence that the law materially changed patient outcomes.
Instead, the public record is underwhelming.
FDA annual reporting summaries on right-to-try use are strikingly sparse. For the reporting period covering 2018 through 2022, the FDA listed 12 eligible drugs and biologics in the consolidated annual summary. For 2023, it listed 4. For 2024, 5. In each of those reporting periods, the agency reported zero cases in which clinical outcomes data from right-to-try use were used in determining safety, and zero cases in which a sponsor requested such use. That is not exactly the stuff of revolution. It is more like a policy echo.
STAT reported in 2024 that the federal law had not lived up to its promise even after six years. KFF Health News, in a fact check examining claims that the program had saved “thousands” of lives, found no evidence supporting that sweeping boast. Peer-reviewed analysis in JAMA Network Open has likewise warned that policymakers seeking to speed access through right-to-try may compromise the balance the FDA and industry had already built between access and patient protection.
That is the heart of the critique: right-to-try generates political theater far more reliably than clinical benefit.
California and beyond: the idea keeps mutating
And yet, like a horror franchise that somehow gets another release date, right-to-try keeps coming back.
California remains part of the story. The state’s original law still exists, and in 2026 lawmakers are considering AB 2489, the California Veterans Right to Try Act. The measure would authorize a state panel to submit an investigational new drug application to the FDA for trials involving Schedule I or Schedule II controlled substances and, if the FDA does not act in time, allow an expedited state approval process under specified conditions. Eligible veterans would need two or more severe or life-threatening mental health conditions and ineligibility for FDA-approved trials.
Supporters will call that bold. Critics will call it a warning label with a smiley face on it.
The California proposal is especially notable because it shows how right-to-try logic has expanded beyond the classic terminal-cancer frame into mental health, psychedelics, and politically charged debates over state power, federal authority, and research access. The same theme is surfacing nationally. In April 2026, the White House directed the FDA and DEA to establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act.
Translation: the old argument is not fading. It is being repackaged for a new set of therapies and a new political moment.
Meanwhile, states keep tinkering. According to the National Conference of State Legislatures, right-to-try now includes 41 states, and several states addressed the issue again in 2025. The policy is not dead. It is evolving, stretching, and in some places becoming even more permissive.
That persistence tells us something important. Right-to-try survives because it is emotionally potent and politically convenient. It lets lawmakers sound compassionate without fixing the more difficult parts of experimental-treatment access: trial design, enrollment inequities, insurer barriers, manufacturer transparency, clinician time, travel burdens, and the infrastructure required to move a fragile patient through a complicated system safely.
What patients actually need instead
If policymakers truly want to help seriously ill patients, there are better targets than another round of right-to-try applause lines.
First, improve access to clinical trials themselves. That means broader eligibility criteria when appropriate, better geographic access, travel and lodging support, multilingual enrollment assistance, and faster referral systems.
Second, strengthen expanded access instead of pretending it does not exist. Educate physicians on how to use it, reduce administrative friction, and make company policies on compassionate use public, consistent, and easier for families to understand.
Third, deal honestly with cost. A right without coverage is often just a permission slip for bankruptcy. Patients need clarity on what insurers, manufacturers, hospitals, and sponsors will pay for before they are asked to chase hope at retail prices.
Fourth, keep real safeguards in place. Desperation should trigger more ethical care, not less. Patients facing life-threatening illness deserve fast decisions, yes, but they also deserve sober counseling about uncertainty, toxicity, odds of benefit, and the possibility that the “last chance” drug may steal time rather than save it.
Experience: what this debate feels like in real life
The right-to-try conversation can sound abstract until you imagine the rooms where it actually lands. In one room, a patient hears that the scan looks worse. In another, a spouse opens a laptop and starts searching for words no family wants to become fluent in. In a third, an oncologist is trying to explain the difference between “investigational,” “accessible,” and “appropriate,” while everyone in the room is hearing only one phrase: there might still be something.
That is the emotional engine of right-to-try. It is not stupidity. It is not gullibility. It is love in a panic.
Families often experience the policy less as law and more as atmosphere. Suddenly there are news clips, fundraising pages, advocacy campaigns, social posts, and stories about a person somewhere who “got access” to something that sounds miraculous. Every anecdote glows. Every caveat whispers. The patient is tired, the caregivers are exhausted, and the phrase “what do we have to lose?” starts sounding less like a question and more like a dare.
But clinicians experience the same moment differently. Many know that early investigational treatments can carry serious toxicity and very low odds of meaningful benefit. They know that some patients are too medically fragile to tolerate another aggressive intervention. They know that companies may decline requests, that shipping timelines can be brutal, and that a family can spend precious weeks chasing paperwork for a treatment that never arrives. Their job is to protect hope without letting hope drive the car straight into a ditch.
There is also the experience of moral whiplash. Patients are told to fight. Families are told not to give up. Lawmakers praise “freedom” and “choice.” Yet when the actual request goes out, reality returns wearing steel-toed boots. The manufacturer may say no. Insurance may say no. The hospital may hesitate. The patient may worsen. A policy that looked heroic on television can feel painfully hollow in a clinic hallway.
Even when access is granted, the experience may not resemble triumph. It can involve travel, debt, side effects, close monitoring, ambiguous results, and the constant fear that the treatment is doing nothing except consuming the little time that remains. Some families still choose that path, and that choice can be understandable. But understanding the choice is not the same as romanticizing the system that produced it.
This is why critics keep calling right-to-try a cruel sham. Not because hope is foolish, but because false hope is expensive. It costs energy, time, money, trust, and sometimes comfort at the exact moment patients can least afford to lose any of them.
At its best, medicine offers candor with compassion. Right-to-try too often offers the opposite: a flattering story about access that leaves families doing the hard part alone.
Conclusion
Right-to-try has lasted because it is emotionally powerful and politically easy. It flatters lawmakers, excites activists, and gives the public a clean villain: regulation. But the real obstacles to investigational treatment access have never fit neatly on a bumper sticker. They involve science, supply, ethics, money, evidence, and timing. That is much less cinematic. It is also much more true.
California’s original law did not end the debate. New proposals in the state, broader state experimentation elsewhere, and the latest federal enthusiasm around psychedelic access show that the movement is still marching. The danger is that it keeps marching past the central lesson: seriously ill patients do not need policy cosplay. They need pathways that are honest, workable, affordable, and medically responsible.
Hope should absolutely have a place in medicine. But hope without evidence, oversight, or practical access is not reform. It is branding. And branding, no matter how moving the slogan, is a lousy substitute for care.
